Casdin Capital

Portfolio Co Investors 2026 for Casdin Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Casdin Capital accounts for 54 tracked companies with verified cap-table data, 54 of which disclose round sizes totalling $10B. The median disclosed raise is $132M, and the largest is Treeline Biosciences at $1.1B, ahead of EQRx ($750M) and Sema4 ($621M).

The names that recur most often on these co-invested cap tables are Casdin Capital (55 companies), Andreessen Horowitz (8 companies), Third Rock Ventures (8 companies), Section 32 (7 companies), Nextech Invest (7 companies), GV (6 companies). By latest disclosed round, the market skews Series B (24), Series C (13), Series A (11), Series E (2).

Best funded Casdin Capital companies

  1. Treeline Biosciences — $1.1B (latest: Series A)
  2. EQRx — $750M (latest: Series B)
  3. Sema4 — $621M (latest: IPO)
  4. Komodo Health — $520M (latest: Series E)
  5. Thrive Earlier Detection — $367M (latest: Series B)
  6. Vividion Therapeutics — $362M (latest: Series B)
  7. Hexagon Bio — $323M (latest: Series B)
  8. Flare Therapeutics — $287M (latest: Series C)
  9. NiKang Therapeutics — $260M (latest: Series C)
  10. Paige — $220M (latest: Series C)
  11. Leyden Labs — $215M (latest: Series A)
  12. Cerevance — $204M (latest: Series B)
  13. BridgeBio Oncology Therapeutics — $200M (latest: Growth)
  14. Asimov — $200M (latest: Series B)
  15. ROME Therapeutics — $199M (latest: Series B)

Casdin Capital — related firms and companies (56)

Casdin Capital profile · All research reports